Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-01-21 8:33 pm Sale |
2025-01-16 | 13D | Verona Pharma plc VRNA |
Growth Equity Opportunities Fund IV, LLC | 32,679,649 4.990% |
-11,998,376 (-26.86%) |
Filing History |
| 2024-08-28 9:51 pm Sale |
2022-09-07 | 13D | Verona Pharma plc VRNA |
Growth Equity Opportunities Fund IV, LLC | 44,678,025 6.900% |
-1,769,626 (-3.81%) |
Filing History |
| 2024-08-14 8:12 pm Sale |
2024-08-12 | 13D | Addex Therapeutics Ltd ADXN |
Growth Equity Opportunities Fund IV, LLC | 0 0.000% |
-6,624,600 (Position Closed) |
Filing History |
| 2024-08-05 9:00 pm Sale |
2024-08-01 | 13D | Addex Therapeutics Ltd ADXN |
Growth Equity Opportunities Fund IV, LLC | 6,624,600 5.100% |
-1,080,000 (-14.02%) |
Filing History |
| 2023-12-08 2:11 pm Purchase |
2023-11-27 | 13D | Addex Therapeutics Ltd ADXN |
Growth Equity Opportunities Fund IV, LLC | 7,704,600 6.400% |
7,704,600 (New Position) |
Filing History |
| 2023-04-10 4:06 pm Unchanged |
2023-04-04 | 13D | Addex Therapeutics Ltd ADXN |
Growth Equity Opportunities Fund IV, LLC | 385,230 8.500% |
0 (Unchanged) |
Filing History |
| 2022-11-28 3:19 pm Unchanged |
2022-11-22 | 13D | Addex Therapeutics Ltd ADXN |
Growth Equity Opportunities Fund IV, LLC | 385,230 9.700% |
0 (Unchanged) |
Filing History |
| 2022-11-01 5:01 pm Sale |
2022-10-20 | 13D | AVEO Pharmaceuticals, Inc. AVEO |
Growth Equity Opportunities Fund IV, LLC | 0 0.000% |
-5,424,009 (Position Closed) |
Filing History |
| 2022-09-07 5:28 pm Purchase |
2022-08-15 | 13D | Verona Pharma plc VRNA |
Growth Equity Opportunities Fund IV, LLC | 46,447,651 7.900% |
3,809,520 (+8.93%) |
Filing History |
| 2022-08-23 5:18 pm Unchanged |
2022-07-26 | 13D | Addex Therapeutics Ltd ADXN |
Growth Equity Opportunities Fund IV, LLC | 385,230 15.100% |
0 (Unchanged) |
Filing History |
| 2022-01-10 1:15 pm Unchanged |
2021-12-16 | 13D | Addex Therapeutics Ltd ADXN |
Growth Equity Opportunities Fund IV, LLC | 385,230 20.400% |
0 (Unchanged) |
Filing History |
| 2021-04-21 5:28 pm Sale |
2021-04-05 | 13D | Affimed N.V. AFMD |
Growth Equity Opportunities Fund IV, LLC | 0 0.000% |
-612,649 (Position Closed) |
Filing History |
| 2021-01-21 6:47 pm Purchase |
2021-01-11 | 13D | Addex Therapeutics Ltd ADXN |
Growth Equity Opportunities Fund IV, LLC | 385,230 21.500% |
385,230 (New Position) |
Filing History |
| 2020-08-03 4:18 pm Purchase |
2020-07-22 | 13D | Verona Pharma plc VRNA |
Growth Equity Opportunities Fund IV, LLC | 42,638,131 10.200% |
31,111,112 (+269.90%) |
Filing History |
| 2020-06-24 5:03 pm Purchase |
2020-06-19 | 13D | AVEO Pharmaceuticals, Inc. AVEO |
Growth Equity Opportunities Fund IV, LLC | 5,424,009 20.800% |
1,428,570 (+35.76%) |
Filing History |